Jaguar Kicks Off Neonorm Foal TV Campaign
& Neonorm Calf Radio Campaign
Sales of Neonorm Calf by Jaguar’s
Distributor ANIMART Up 167% in February 2017 Compared to February
2016
Napo Launches National Sales Force for
Mytesi
Mytesi Study Abstract Selected for
Presentation as Poster Exhibition at July’s International AIDS
Society Conference on HIV Science
Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal
health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and
production animals, foals, and high value horses, and Napo
Pharmaceuticals, Inc. (“Napo”), a human health company developing
and commercializing novel gastrointestinal prescription products
from plants used traditionally in rainforest areas, today announced
the following commercial updates.
Neonorm Sales & Marketing
Jaguar is launching a national TV advertising campaign this
month for Neonorm™ Foal and a radio campaign in key dairy markets
for Neonorm™ Calf. Neonorm™ Foal and Neonorm™ Calf are Jaguar’s
lead non-prescription products.
Neonorm™ Foal is a natural, clinically-tested, non-drug product
designed for use as an anti-diarrheal in newborn horses. Diarrhea
is one of the most common clinical complaints in foals, especially
within the first 30 days of life. The crippling effects of
dehydration that often result from secretory diarrhea in foals can
manifest quickly, precipitate adverse health effects and lead to
death. Neonorm™ Calf has been formulated and clinically tested to
help proactively retain fluid in dairy calves and reduce the
severity of diarrhea—aiding calves in avoiding debilitating,
dangerous levels of dehydration associated with scours.
Jaguar’s Neonorm™ Foal TV campaign will consist of a 30-second
commercial that will air during evening prime time hours this month
on RFD-TV, a 24-hour television network featuring equine
programming as well as content focused on agribusiness and the
rural lifestyle. The TV spot, which features noted foal medicine
specialist Dr. Siobhan McAuliffe, MVB, DACVIM, can be viewed at
https://www.youtube.com/watch?v=f1PzUnKWgHU&feature=youtu.be.
Jaguar’s radio campaign for Neonorm™ Calf consists of a
30-second spot airing this month during early morning hours on
“DairyLine”, a national program regarded as the dairy industry’s
premiere radio voice. On the air for more than 20 years and running
on more than 40 stations across 16 states, “DairyLine” has strong
coverage across all dairy producing regions in the U.S., including
Wisconsin, California and New York. The radio spot can be heard on
Jaguar’s blog at https://jaguaranimalhealth.com/dairyline.
The TV and radio ads feature two new contact channels created to
help support sales and build the Neonorm brand: Jaguar’s new
Neonorm.com web address and a new toll-free hotline: 844-NEONORM.
In support of sales efforts, Jaguar also recently created an
e-commerce area on the Company’s corporate website that allows
end-user customers to purchase Neonorm™ Calf and Neonorm™ Foal
directly from Jaguar, and launched a content-filled blog:
https://jaguaranimalhealth.com/blog. Additionally, the Company has
been actively targeting dairy farmers, equine veterinarians, bovine
veterinarians, and the owners, breeders and trainers of horses, via
Facebook, Instagram and Twitter during Q1 2017 as part of further
efforts to drive exposure, build a community of engaged followers,
and support Neonorm sales. Jaguar also teamed with ANIMART, LLC,
the Company’s dairy market distributor, to conduct “Lunch n’ Learn”
events in Midwest dairy regions in Q1 2017 to help increase
awareness of the benefits and novel mechanism of action of Neonorm™
Calf among ANIMART’s dairy customers.
“The integrated, multichannel marketing initiatives Jaguar has
launched over the past four months in support of Neonorm™ Foal and
Neonorm™ Calf are all aligned with our Neonorm™ commercial strategy
of connecting directly with dairy farmers, vets, horse owners and
other members of the equine community, in a targeted and engaging
way, to help build the Neonorm™ brand and drive sales—both directly
and through our core dairy market distributor, ANIMART, and our
exclusive distributor for Neonorm™ Foal, Henry Schein,” commented
Lisa Conte, Jaguar’s president and CEO.
ANIMART sales of Neonorm™ Calf, measured by the total number of
Neonorm™ Calf boluses sold, are up 167% for February 2017 compared
to February 2016.
Neonorm™ is a standardized botanical extract derived from the
Croton lechleri tree that acts at the same last step in a
physiological pathway generally present in mammals. Foaling season
in the northern hemisphere generally runs from May through
September, while calf scours season in the U.S. generally runs from
March through June.
Napo Launches National Sales Force to Promote and Provide
Samples of Mytesi™ to HIV Healthcare
Providers
As announced February 28, 2017, Napo has signed an agreement
with Alamo Pharma Services, Inc. for the establishment and
management of a national sales team for Mytesi™. The launch of the
sales force took place this week. Mytesi™, launched by Napo in
October 2016, is approved by the U.S. FDA for the symptomatic
relief of noninfectious diarrhea in adults with HIV/AIDS on
antiretroviral therapy. Alamo is providing a team of shared sales
representatives to supplement the dedicated Napo representatives to
promote and sample Mytesi™ in key metropolitan areas throughout the
United States. The sales representatives have begun reaching out to
doctors who have large populations of HIV patients and, therefore,
are high-volume prescribers of antiretroviral therapies.
Napo and Jaguar estimate the potential U.S. market for Mytesi™
to be approximately $100 million in gross annual sales, and
forecast that Mytesi™ will generate approximately $7.0 million in
net sales in 2017, with the greatest impact on prescription growth
coincident with the deployment of the sales force and sampling
program.
Mytesi™ Study Abstract Selected for
Presentation as a Poster Exhibition at the 2017 International AIDS
Society Conference on HIV Science
An abstract based on new crofelemer (Mytesi™) data from a
supplemental analysis of the Napo-sponsored ADVENT trial has been
accepted for presentation as a poster exhibition at the 9th IAS
Conference on HIV Science (IAS 2017), to be held in Paris, France,
July 23-26, 2017.
Canalevia™ for Use in Dogs with
Chemotherapy-Induced Diarrhea (CID)
As previously announced, Jaguar expects Canalevia™ for the
indication of CID in dogs to be the Company’s first drug product
candidate available commercially. Pending FDA approval of
Canalevia™ for CID, Jaguar expects to conduct the commercial launch
of Canalevia™ for this indication in the next year. Jaguar’s lead
drug product candidate, under investigation for various types of
diarrhea in dogs, Canalevia™ is a canine-specific formulation of
crofelemer, an active pharmaceutical ingredient isolated and
purified from the Croton lechleri tree, which is sustainably
harvested. Numerous animal and human clinical trials have shown
significant beneficial results in the use of crofelemer in the
treatment of secretory diarrhea.
Proposed Merger
As announced March 31, 2017, Jaguar and Napo have entered a
definitive merger agreement. The proposed merger remains subject to
customary conditions to closing. Upon the consummation of the
merger, Jaguar’s name will be changed to Jaguar Health, Inc., and
Napo will operate as a wholly-owned subsidiary of Jaguar, focused
on human health. Subject to the conditions to closing, the proposed
merger is expected to close during the second quarter of 2017.
About Mytesi™
Mytesi™ (crofelemer 125mg delayed-release tablets) is an
antidiarrheal indicated for the symptomatic relief of noninfectious
diarrhea in adult patients with HIV/AIDS on antiretroviral therapy
(ART). Mytesi™ is not indicated for the treatment of infectious
diarrhea. Rule out infectious etiologies of diarrhea before
starting Mytesi™. If infectious etiologies are not considered,
there is a risk that patients with infectious etiologies will not
receive the appropriate therapy and their disease may worsen. In
clinical studies, the most common adverse reactions occurring at a
rate greater than placebo were upper respiratory tract infection
(5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and
increased bilirubin (3.1%). Please see complete Prescribing
Information available at Mytesi.com
About Napo Pharmaceuticals, Inc.
San Francisco-based Napo Pharmaceuticals, Inc. focuses on the
development and commercialization of proprietary pharmaceuticals
for the global marketplace in collaboration with local
partners.
For more information, please visit www.napopharma.com.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused
on developing and commercializing first-in-class gastrointestinal
products for companion and production animals, foals, and high
value horses. Canalevia™ is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea
in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s
prescription drug product candidate for the treatment of
gastrointestinal ulcers in horses. Canalevia™ and Equilevia™
contain ingredients isolated and purified from the Croton lechleri
tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™
Foal are the Company’s lead non-prescription products. Neonorm™ is
a standardized botanical extract derived from the Croton lechleri
tree. Canalevia™ and Neonorm™ are distinct products that act at the
same last step in a physiological pathway generally present in
mammals. Jaguar has nine active investigational new animal drug
applications, or INADs, filed with the FDA and intends to develop
species-specific formulations of Neonorm™ in six additional target
species, formulations of Equilevia™ in horses, and Canalevia™ for
cats and dogs.
For more information about Jaguar, please visit
www.jaguaranimalhealth.com.
Additional Description of the Proposed Merger
As announced March 31, 2017, Jaguar and Napo Pharmaceuticals,
Inc. (“Napo”) have entered a definitive merger agreement (the
“Agreement”). Upon the consummation of the merger, Jaguar’s name
will be changed to Jaguar Health, Inc., and Napo will operate as a
wholly-owned subsidiary of Jaguar, focused on human health.
Following consummation of the proposed merger, it is expected that
there will be approximately 65 million shares outstanding in the
combined entity. The balance of the outstanding fully diluted
equity of the combined entity, when factoring in convertible debt,
is expected to be approximately 93 million shares following
consummation of the proposed merger. These share counts are based
on a relative company valuation, per the merger terms, of Napo to
Jaguar of approximately 3:1.
Important Additional Information will be Filed with the
SEC
This press release may be deemed solicitation material regarding
the intended merger between Jaguar and Napo. Jaguar currently
intends to file with the SEC a Registration Statement on Form S-4
that will include a proxy solicitation. Jaguar also plans to file
other relevant materials with the SEC. Stockholders of Jaguar and
Napo are urged to read the proxy solicitation/prospectus contained
in the Registration Statement when it becomes available and any
other relevant materials filed with the SEC because these materials
will contain important information about the potential merger. Once
available, these materials will be made available to the
stockholders of Jaguar and Napo at no expense to them. The
Registration Statement, proxy statement/prospectus and other
relevant materials, including any documents incorporated by
reference therein, once available, may be obtained free of charge
at the SEC’s website at www.sec.gov or from Jaguar at
www.jaguaranimalhealth.com or by emailing grussell@kcsa.com.
Jaguar and certain of its directors and executive officers may
be deemed to be participants in the solicitation of proxies in
connection with the potential merger. Information about the
executive officers and directors of Jaguar is set forth in Jaguar’s
Annual Report on Form 10-K for the fiscal year ended December 31,
2016 as filed with the SEC on February 15, 2017 and Definitive
Proxy Statement for the 2016 Annual Meeting of Stockholders of
Jaguar filed with the SEC on April 29, 2016.
Notice as to Unregistered Securities
In connection with the intended merger, shares of common stock
and other securities of Jaguar have been and will be offered to
accredited institutional and individual investors pursuant to one
or more exemptions from registration under the Securities Act of
1933, as amended (the “Securities Act”). These securities have not
been registered under the Securities Act or the securities laws of
any other jurisdiction and may not be offered or sold in the U.S.
absent registration or an applicable exemption from registration
requirements.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements.” These include statements regarding
Napo’s and Jaguar’s estimate that the potential U.S. market for
Mytesi™ is approximately $100 million in gross annual sales, Napo’s
and Jaguar’s forecast that Mytesi™ will generate approximately $7.0
million in net sales in 2017, with the greatest impact on
prescription growth coincident with the deployment of the sales
force and sampling program, Jaguar’s expectation that Canalevia™
for the indication of CID in dogs will be the Company’s first drug
product candidate available commercially, and that, pending FDA
approval of Canalevia™ for CID, Jaguar expects to conduct the
commercial launch of Canalevia™ for this indication in the next
year, the structure, timing and completion of the proposed merger
or Napo debt settlement, expectations regarding the capitalization,
resources and ownership structure of the combined company, the
expectation that the merger conditions to closing will be
satisfied, Jaguar’s intention to develop species-specific
formulations of Neonorm™ in additional target species, and the
Company’s plan to develop formulations of Canalevia™ for cats,
horses and dogs. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,”
“plan,” “aim,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negative of these terms or other
similar expressions. The forward-looking statements in this release
are only predictions. Jaguar has based these forward-looking
statements largely on its current expectations and projections
about future events. These forward-looking statements speak only as
of the date of this release and are subject to a number of risks,
uncertainties and assumptions, some of which cannot be predicted or
quantified and some of which are beyond Jaguar’s control. Except as
required by applicable law, Jaguar does not plan to publicly update
or revise any forward-looking statements contained herein, whether
as a result of any new information, future events, changed
circumstances or otherwise.
Jaguar-JAGX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170406005574/en/
KCSA Strategic CommunicationsGarth Russell,
212-896-1250grussell@kcsa.com
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jul 2023 to Jul 2024